Unknown

Dataset Information

0

Clinical utility of plasma miR-371a-3p in germ cell tumors.


ABSTRACT: Germ cell tumours predominantly of the testis ((T)GCTs) are remarkably chemotherapy sensitive. However, a small proportion of patients fail to be cured with cisplatin-based combination chemotherapy. miR-371a-3p is a new liquid biopsy biomarker for (T)GCTs. The aim of this study was to evaluate clinical utility of plasma miR-371a-3p level in patients starting systemic chemotherapy. Patients were included before the first cycle (N = 180) and second cycle (N = 101) of systemic first line chemotherapy, treated between July 2010 and May 2017. Plasma miR-371a-3p levels were measured with the ampTSmiR test and compared to disease characteristics and outcome. Pretreatment plasma miR-371a-3p levels were increased in 51.7% of cases and associated with number of metastatic sites, presence of lung, retroperitoneal, and mediastinal lymph node metastases, S - stage, IGCCCG risk group, and response to therapy. Patients with a negative pretreatment plasma level had better progression-free survival (PFS) and overall survival (OS) compared to patients being positive for miR-371a-3p (hazard ratio [HR] = 0.26, 95% confidence interval [CI] 0.09-0.71, P = 0.02 for PFS and HR = 0.21, 95% CI 0.07-0.67, P = 0.03 for OS, respectively). Patients negative for miR-371a-3p in both samples had a superior PFS (HR = 0.10, 95% CI 0.01-21.49, P = 0.02) and OS (HR = 0.08, 95% CI 0.01-27.81, P = 0.008) compared to patients with miR-371a-3p positive in both samples (multivariate analyses were non-significant). In total 68% of the patients were S0. This study demonstrates clinical value of plasma miR-371a-3p level in chemotherapy naïve (T)GCT patients starting first line of chemotherapy to predict prognosis.

SUBMITTER: Mego M 

PROVIDER: S-EPMC6349199 | BioStudies | 2019-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7140045 | BioStudies
2020-01-01 | S-EPMC7185068 | BioStudies
1000-01-01 | S-EPMC6039090 | BioStudies
2019-01-01 | S-EPMC6830325 | BioStudies
1000-01-01 | S-EPMC6213366 | BioStudies
1000-01-01 | S-EPMC4815809 | BioStudies
2019-01-01 | S-EPMC6767197 | BioStudies
1000-01-01 | S-EPMC5833456 | BioStudies
2015-01-01 | S-EPMC4612782 | BioStudies
2018-01-01 | S-EPMC5915726 | BioStudies